Regenesis Orthobiologics is seeking an investment of £1.2 million to revolutionize musculoskeletal healthcare by establishing state-of-the-art regenerative therapy clinics. Leveraging its position as one of the UK’s top five genetic and cell-based therapy providers in 2024, Regenesis delivers cutting-edge, non-surgical treatments for osteoarthritis, sports injuries, and other musculoskeletal conditions. These therapies utilize advanced techniques like stem cells, PRP, and visco-supplementation to enhance healing, reduce pain, and improve mobility.
With a proven business model and market traction, including a lifetime patient value (LTV) of £2,600 and a 6.5 LTV-to-CAC ratio, Regenesis has demonstrated its potential for profitability from year one. The funding will support the development of two clinics, with projected first-year revenue of £4.8 million and a five-year growth trajectory to £25.8 million. The flagship clinic in Manchester is already set to lead, with a second in Harley Street, London, following shortly. Additionally, international expansion plans are in motion, targeting regions like the UAE, Nigeria, and Turkey.
Regenesis stands out with its innovative, evidence-based protocols, a focus on personalized care, and holistic solutions such as genetic screening and biohacking. With a valuation of £24 million, an IRR of 29%, and dividends starting in the first year, Regenesis offers investors a lucrative opportunity to impact healthcare globally while achieving strong returns.
The investment opportunity offers a 10% equity stake in Regenesis Orthobiologics for £1.2 million, with funds allocated to capital expenditures, equipment, clinical and non-clinical staff, marketing, and operational costs. The business projects a payback period of four years, supported by robust financial projections, including a first-year revenue of £4.8 million and a five-year growth to £25.8 million. With a valuation of £24 million and an internal rate of return (IRR) of 29%, investors can expect dividends from the first year, providing an attractive balance of near-term returns and long-term growth potential. This opportunity allows investors to be part of a pioneering healthcare venture with proven market traction and significant scalability.
